One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.